Microbot Medical Appoints Eyal Morag M.D. as Chief Medical Officer
03 Março 2020 - 09:00AM
Microbot Medical Inc. (NASDAQ: MBOT), announced the appointment of
Eyal Morag, M.D., a leading radiologist, to Chief Medical Officer,
effective immediately. In his new role, Dr. Morag will lead the
development and execution of the clinical strategy of the Company’s
technology platforms, including its current development of the
Self-Cleaning Shunt (SCS) and LIBERTY products as well as its
future pipeline. Dr. Morag has been a member of the Company’s
Scientific Advisory Board since November 2017 and will report
directly to Harel Gadot, Chief Executive Officer, President, and
Chairman.
“Dr. Morag is highly-regarded in the radiology
community, and has been a valued member of our Scientific Advisory
Board, having played an integral part in the creation of our
LIBERTY device. I am pleased that he sees the potential in our
endovascular solutions, and as such joined us full-time to become
part of our leadership team,” commented Mr. Gadot. “I am confident
his contributions to date, combined with his expertise and
experience, will allow us to achieve our near- and long-term
development, regulatory, and commercialization plans.”
“Microbot Medical’s innovative technologies are
at a critical junction point, transitioning from product
development to focus more on clinical validation and regulatory
phases,” said Dr. Morag. “I am excited to join the Company, and to
be part of Microbot’s talented team on our mission to improve
outcomes and safety by bringing novel endovascular tools to
patients and clinicians.”
Dr. Morag is certified by the American Board of
Radiology and until recently served as Chairman of Radiology at
Assuta Ashdod Medical Center, Ashdod, Israel. He is a graduate of
Boston University School of Medicine and completed both his
Radiology residency and Fellowship in Cardiovascular &
Interventional Radiology at the Beth Israel Deaconess Medical
Center & Harvard Medical School. Following his clinical
training, Dr. Morag joined a private practice in western
Massachusetts, where he served as Chief of Radiology at Holyoke
Medical Center for several years. He has also served as the
Regional Radiology Director at Mercy Health Partners Hospitals in
Toledo, Ohio, and was a member of the University Radiology Group
(one of the largest private Radiology groups in the U.S.) where he
headed the International Investment efforts for the Ventures
division.
Dr. Morag’s extensive international experience
developing and establishing radiology-related businesses includes
teleradiology, interventional Radiology services, and free-standing
imaging centers. During his fellowship, Dr. Morag co-founded InTek
Technology, a medical device startup company. Later he founded
Global Versa Radiology (GVR), an Israeli and U.S. based
Teleradiology Company that has expanded reach to provide
Interventional Radiology services to U.S. hospitals. GVR has
established imaging centers in Russia and Ukraine and provided
teleradiology services in countries outside the U.S. and Israel.
Dr. Morag has served as GVR’s Chief Medical Officer and
Vice-President.
About Microbot Medical Inc.
Microbot Medical Inc. (MBOT) is a pre-clinical
medical device company that specializes in transformational
micro-robotic technologies, focused primarily on both natural and
artificial lumens within the human body. Microbot’s current
proprietary technology platforms provide the foundation for the
development of a Multi-Generation Pipeline Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein to improve clinical
outcomes for patients and increase accessibility through the use of
micro-robotic technologies. Further information about Microbot
Medical is available at http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, the
outcome of its studies to evaluate the SCS, LIBERTY and other
existing and future technologies, uncertainty in the results of
pre-clinical and clinical trials or regulatory pathways and
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the businesses of Microbot
Medical Inc. particularly those mentioned in the cautionary
statements found in Microbot Medical Inc.’s filings with the
Securities and Exchange Commission. Microbot Medical disclaims any
intent or obligation to update these forward-looking
statements.
Investor Contact:
Michael PolyviouEVC
Groupmpolyviou@evcgroup.com732-933-2754
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9e59d93a-e73d-4e85-8f97-5a43f1b3da84
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Microbot Medical (NASDAQ:MBOT)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024